Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

Study population text

Adults residing in the United States who are current users of GLP-1 receptor agonist medications for type 2 diabetes, overweight or obesity, and/or weight management. Participants are recruited from community and online settings rather than from a single physical site. Sources include: IRB-approved flyers and posters displayed in relevant clinical settings (e.g., endocrinology, primary care) and community locations; social media outreach (posts and advertisements) directed at adults using GLP-1 receptor agonist medications; and clinic-based outreach in which participating clinic staff post handouts in waiting areas or distribute them to potentially interested patients during routine visits. Interested individuals self-refer by accessing an anonymous online Qualtrics survey link. The study team does not pre-screen, identify, or contact patients directly, and does not access medical records or protected health information at any point.